Efforts to find a "magic pill" for Alzheimer's disease have largely overlooked a critical factor: the overactivation of the brain's specialized immune cells, known as microglia, according to neurologist Dr. David Perlmutter.
Perlmutter, in an adaptation of his book "Brain Defenders," explains that microglia, which normally function to clear cellular debris and maintain brain health, can become detrimental when they shift from their supportive M2 state to an inflammatory M1 state. This shift can be triggered by aging, poor diet, gut inflammation, and other lifestyle factors, leading to damage to brain cells and synapses, and contributing to the formation of beta-amyloid plaques.
While pharmaceutical companies have invested heavily in targeting beta-amyloid, Perlmutter suggests that optimizing microglial function presents a more promising avenue for Alzheimer's prevention and treatment. He notes that lifestyle changes, including regular exercise and a diet rich in fiber and low in ultra-processed foods, can positively influence microglia. Furthermore, several existing medications and common dietary supplements show potential in supporting healthier microglial activity.
Medications like metformin, originally developed for type 2 diabetes, are being studied for their positive effects on mitochondria and insulin sensitivity, which can help reduce microglial overactivation. The upcoming Targeting Aging with Metformin (TAME) trial is expected to explore metformin's potential as an anti-aging drug with implications for cognitive decline.
GLP-1 agonists, such as Ozempic, have also shown remarkable potential. Studies suggest these drugs can directly bind to microglia, reducing neuroinflammation and increasing levels of brain-derived neurotrophic factor (BDNF), a protein crucial for neuron health. Research published in "Alzheimer's & Dementia" indicated a significantly lower risk of Alzheimer's diagnosis in type 2 diabetes patients treated with Ozempic. A clinical trial in the UK also suggested that liraglutide, another GLP-1 drug, could slow cognitive decline and reduce brain cell loss in Alzheimer's patients.
Other medications like minocycline, an antibiotic with anti-inflammatory properties, and dimethyl fumarate, used to treat multiple sclerosis, are also being investigated for their ability to inhibit microglial activation and reduce neuroinflammation.
Beyond prescription drugs, Perlmutter highlights several supplements that can support microglial health. Docosahexaenoic acid (DHA), an omega-3 fatty acid, is a key structural component of brain cell membranes and has potent anti-inflammatory properties. Creatine is suggested to aid energy transfer to synapses and enhance mitochondrial function, potentially improving cognitive abilities. Magnesium, particularly magnesium threonate, is noted for its role in nerve function and stress reduction, indirectly benefiting microglia by enhancing mitochondrial function.
Probiotics are recommended due to the established link between gut health and brain inflammation. MitoQ10, a synthetic form of coenzyme Q10, is designed to protect mitochondria and may reduce neuron death in Alzheimer's. Sprouted Himalayan tartary buckwheat, rich in polyphenols, is also noted for its antioxidant and mitochondrial-supporting benefits.
Perlmutter emphasizes that while supplements can be strategic tools, they should not replace a healthy diet. He advises consulting with a healthcare professional before starting any new supplement regimen, especially for individuals with pre-existing health conditions or those taking other medications.